SEC Form 4 · accession 0001179110-15-004404
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John D Quisel
Officer — SVP Gen. Counsel & Secretary
Period of report
Mar 4, 2015
Accepted (ET)
Mar 6, 2015 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 4, 2015 | M | 2,000 | $1.80 | A | 17,000 | D | |
| Common Stock | Mar 4, 2015 | M | 2,000 | $5.08 | A | 19,000 | D | |
| Common StockF2 | Mar 4, 2015 | S | 2,699 | $40.65 | D | 16,301 | D | |
| Common StockF3 | Mar 4, 2015 | S | 1,300 | $41.50 | D | 15,001 | D | |
| Common Stock | Mar 4, 2015 | S | 1 | $42.07 | D | 15,000 | D | |
| Common Stock | Mar 4, 2015 | M | 5,500 | $5.88 | A | 20,500 | D | |
| Common StockF4 | Mar 4, 2015 | S | 4,333 | $40.34 | D | 16,167 | D | |
| Common StockF5 | Mar 4, 2015 | S | 1,066 | $41.77 | D | 15,101 | D | |
| Common StockF6 | Mar 4, 2015 | S | 101 | $42.06 | D | 15,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF7 | $1.80 | Mar 4, 2015 | M | 2,000 | D | — | Jun 12, 2017 | Common Stock | 2,000 | 0 | D |
| Option to Purchase Common StockF7 | $5.08 | Mar 4, 2015 | M | 2,000 | D | — | Mar 27, 2018 | Common Stock | 2,000 | 4,000 | D |
| Option to Purchase Common StockF7 | $5.88 | Mar 4, 2015 | M | 5,500 | D | — | Dec 17, 2018 | Common Stock | 5,500 | 1,461 | D |
Explanation of responses
- F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.06 to $41.05, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.06 to $42.04, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.06 to $42.04, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $42.07, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4.
- F7The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.